Alembic Pharmaceuticals Limited concluded its 16th Annual General Meeting (AGM) on August 5, 2026, approving its financial results for the fiscal year ended March 31, 2026, and finalizing key board appointments. The meeting, conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM), allowed shareholders to vote on ordinary and special business items, including the declaration of dividends and the ratification of cost auditor remuneration for the upcoming financial year.

The proceedings were filed in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Manisha Saraf, Company Secretary, confirmed the presence of quorum and declared the meeting open at 4:00 P.M. IST. The meeting was attended by 78 members, with all directors present except Independent Directors Manish Kejriwal and Geeta Goradia. Tejas Parikh of KKC & Associates LLP served as Statutory Auditor, while S. Samdani of Samdani Shah & Kabra acted as Secretarial Auditor and Scrutinizer.

Ordinary Business Transactions

Shareholders addressed three primary items under ordinary business. The first resolution involved receiving, considering, and adopting the Audited Standalone Financial Statements for the financial year ended March 31, 2026, alongside the Board of Directors’ and Auditors’ reports. The second item concerned the adoption of the Audited Consolidated Financial Statements for the same period, together with the Auditors’ reports. The third resolution focused on declaring dividends on equity shares for the financial year 2025-26.

Additionally, shareholders voted to re-appoint Pranav Amin (DIN: 00245099) as a director. Mr. Amin retired by rotation during the meeting but, being eligible, offered himself for re-appointment to the Board.

Special Business Appointments

Under special business, the company sought approval for two significant governance changes. First, shareholders approved the appointment of Sujit Jaysukh Bhayani (DIN: 01767427) as an Independent Director. Second, the meeting ratified the remuneration payable to the Cost Auditors for the financial year 2026-27.

Chairman Chirayu Amin delivered a statement on the company’s affairs, after which Managing Directors Pranav Amin and Shaunak Amin, along with CFO G. Krishnan, responded to queries from registered members. Voting continued for 15 minutes post-meeting to allow additional participation, with results scheduled for declaration by August 7, 2026.

Alembic Pharmaceuticals reported a consolidated net profit of ₹173.07 crore for the quarter ended June 30, 2026, marking a 12.1% increase from ₹154.38 crore in the corresponding period of the previous year. The company’s revenue from operations grew to ₹2,149.77 crore, up 26% year-on-year, driven primarily by a 49% surge in its US formulation business. This performance underscores the company’s expanding global footprint and operational efficiency during the initial quarter of FY27, with broad-based growth across all key segments.

Consolidated Financial Performance

The Board of Directors approved the unaudited consolidated financial results on August 4, 2026. Statutory auditors KKC & Associates LLP issued an unqualified review report on the statements. Key consolidated metrics for the quarter are detailed below:

*Note: Previous year EBITDA Pre-R&D derived from current year growth rate and reported figure.

EBITDA pre-R&D increased to ₹523 crore, representing a margin of 24%. Regulatory disclosures under Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, were included in the filing. The company also filed its results under Regulation 30 of the same regulations on August 5, 2026.

Segment-Wise Revenue Breakdown

The investor presentation highlighted strong growth across all business verticals. The US Formulation segment emerged as the primary growth driver, with revenues jumping to ₹778 crore from ₹523 crore in Q1FY26. This was supported by seven new product launches and volume gains. The API segment also showed robust health, growing 33% year-on-year to ₹346 crore, backed by a strong order book. India Branded Business grew 7% to ₹642 crore, while Ex-US Formulation rose 17% to ₹383 crore.

Management Commentary and Pipeline

Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, stated that the company started FY27 on a strong note with broad-based growth across businesses. He attributed the performance to healthy volume growth, successful new product launches, and continued execution across key markets. Amin noted that the US business delivered strong momentum while other markets recorded steady growth. The company remains focused on strengthening its product portfolio and advancing its pipeline.

In the US market, Alembic launched seven new products in Q1FY27, bringing the total commercialized portfolio to 185 products. The company received 10 ANDA approvals during the quarter and has 244 approved ANDAs in total, including 20 tentative approvals. A pipeline of 15+ product launches is expected in FY27. R&D spending increased 29% year-on-year to ₹1.86 billion, representing 9% of revenue, focusing on peptide development and complex platforms.

Standalone Results and Balance Sheet Health

On a standalone basis, Alembic Pharmaceuticals reported a net profit of ₹196.96 crore for Q1FY27, a substantial rise from ₹103.52 crore in Q1FY26. Standalone revenue reached ₹1,868.06 crore, up from ₹1,494.17 crore in the same quarter last year. The standalone operating margin expanded to 19.26% from 14.83% year-on-year, indicating improved cost management at the parent company level.

The company’s balance sheet remains robust with a debt-equity ratio of 0.28 times for the consolidated entity and 0.22 times for the standalone entity. Net worth increased to ₹5,856.21 crore (consolidated) and ₹5,819.40 crore (standalone). The current ratio was maintained at 1.69 times (consolidated) and 1.75 times (standalone), reflecting healthy liquidity positions.